Li Chunyan, Peng Yan, Mao Binglang, Qian Kun
Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Biotherapy Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Oncotarget. 2015 Jul 10;6(19):17792-804. doi: 10.18632/oncotarget.3785.
Here we found that hepatocellular carcinoma (HCC) patients with recurrence outcome and nonsurvivors had significantly increased thioredoxin reductase (TrxR) serum levels on reoperation (P < 0.0001 and P < 0.0001). Multivariate regression analysis adjusted for common risk factors showed that TrxR was an independent predictor of recurrence (hazard ratios [HR] = 4.19; 95% confidence intervals [CI]: 3.21-7.08) and overall survival (HR = 5.56; 95% CI: 3.42-10.21). The area under the receiver operating characteristic curve of TrxR was 0.837 (95% CI, 0.794-0.881) for recurrence outcome and 0.901 (95% CI, 0.869-0.933) for mortality, which was superior to high-sensitivity-C-reactive protein and a-fetoprotein (P < 0.001). The preoperative serum TrxR level is an independent and significant indicator predictive of poor prognosis and early recurrence in patients with HCC, which offering reliable information for predicting survival.
在此我们发现，复发的肝细胞癌（HCC）患者及非幸存者再次手术时血清硫氧还蛋白还原酶（TrxR）水平显著升高（P < 0.0001和P < 0.0001）。针对常见风险因素进行多变量回归分析显示，TrxR是复发（风险比[HR]=4.19；95%置信区间[CI]：3.21 - 7.08）和总生存期（HR = 5.56；95% CI：3.42 - 10.21）的独立预测指标。TrxR的受试者工作特征曲线下面积，对于复发结局为0.837（95% CI，0.794 - 0.881），对于死亡率为0.901（95% CI，0.869 - 0.933），优于高敏C反应蛋白和甲胎蛋白（P < 0.001）。术前血清TrxR水平是预测HCC患者预后不良和早期复发的独立且重要的指标，可为预测生存提供可靠信息。
